AR052618A1 - ANTIBODIES ANTI- INTERFERED GAMMA AND METHODS OF USING THEMSELVES - Google Patents

ANTIBODIES ANTI- INTERFERED GAMMA AND METHODS OF USING THEMSELVES

Info

Publication number
AR052618A1
AR052618A1 ARP060101076A AR052618A1 AR 052618 A1 AR052618 A1 AR 052618A1 AR P060101076 A ARP060101076 A AR P060101076A AR 052618 A1 AR052618 A1 AR 052618A1
Authority
AR
Argentina
Prior art keywords
ifngamma
gamma
interfered
themselves
methods
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Walter Ferlin
Nicolas Fischer
Greg Elson
Oliver Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Priority to ARP060101076 priority Critical patent/AR052618A1/en
Publication of AR052618A1 publication Critical patent/AR052618A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a anticuerpos completamente humanos y fragmentos de los mismo, que se unen al interferon gamma humano (hIFNgamma), modulando así la interaccion entre IFNgamma y, su receptor, IFNgamma-R, y/o modular las actividades biologicas de IFNgamma. La presente además se refiere al uso de dichos anticuerpos anti-IFNgamma para la prevencion o tratamiento de trastornos relacionados con el sistema inmunologico y la mejora de un síntoma asociado con un trastorno relacionado con el sistema inmunologico.This refers to fully human antibodies and fragments thereof, which bind to human interferon gamma (hIFNgamma), thus modulating the interaction between IFNgamma and its receptor, IFNgamma-R, and / or modulating the biological activities of IFNgamma. The present further refers to the use of said anti-IFNgamma antibodies for the prevention or treatment of disorders related to the immune system and the improvement of a symptom associated with a disorder related to the immune system.

ARP060101076 2006-03-20 2006-03-20 ANTIBODIES ANTI- INTERFERED GAMMA AND METHODS OF USING THEMSELVES AR052618A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP060101076 AR052618A1 (en) 2006-03-20 2006-03-20 ANTIBODIES ANTI- INTERFERED GAMMA AND METHODS OF USING THEMSELVES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP060101076 AR052618A1 (en) 2006-03-20 2006-03-20 ANTIBODIES ANTI- INTERFERED GAMMA AND METHODS OF USING THEMSELVES

Publications (1)

Publication Number Publication Date
AR052618A1 true AR052618A1 (en) 2007-03-21

Family

ID=37908445

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101076 AR052618A1 (en) 2006-03-20 2006-03-20 ANTIBODIES ANTI- INTERFERED GAMMA AND METHODS OF USING THEMSELVES

Country Status (1)

Country Link
AR (1) AR052618A1 (en)

Similar Documents

Publication Publication Date Title
NO20073882L (en) Human anti-interferon gamma antibodies and methods for their use
CO6280500A2 (en) SPECIFIC HUMANIZED ANTIBODIES PARE L VON WILLEBRAND FACTOR
BR112019012354A2 (en) anti-bcma heavy chain antibodies only
CU24058B1 (en) PCSK9 ANTAGONISTS
CL2008000691A1 (en) COMPOUNDS DERIVED FROM DIHIDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONAS REPLACED; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CHICHOPHRENIA, EPILEPSY, BETWEEN OTHER DISEASES.
AR078346A1 (en) HUMAN HIGH AFFINITY ANTIBODIES AGAINST THE RECEPTOR ACTIVATED BY HUMAN TYPE 2 PROTEASE
UY31114A1 (en) HUMANIZED ANTIBODIES AGAINST AB GLOBULOMER (20-42) AND ITS USES
NI201000281A (en) HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVED THEREOF, AND THEIR USE.
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
CL2008001826A1 (en) Methods and composition for the treatment of allergic diseases human stromal lymphopoietin receptor antibody (tslp) or antigen-binding portion thereof; polynucleotide that encodes it; host cell; pharmaceutical composition comprising it; and its use to treat an inflammatory disease or disorder in a subject
ECSP11011115A (en) ANTI-PD-L1 ANTIBODIES AND THEIR USE TO IMPROVE THE FUNCTION OF T-CELLS
CL2007003726A1 (en) ANTI-RECEIVER ANTIBODIES OF THE INSULIN I SIMILAR GROWTH FACTOR (IGF-IR); PHARMACEUTICAL COMPOSITION CONTAINING IT; AND ITS USE TO TREAT CANCER.
ECSP13012436A (en) BETA AMILOID ANTI-N3pGlu PEPTIDE ANTIBODIES AND USES OF THE SAME
GT200600240A (en) ANTI-TRKB MONOCLONAL ANTIBODIES AND USES OF THE SAME
UY29283A1 (en) AB (BETA) ANTIBODIES USED TO IMPROVE COGNITION
CL2010001538A1 (en) Compounds derived from substituted pyrazolo-quinazoline, modulators of the activity of protein kinases; pharmaceutical composition; and its use for the treatment of cancer, or a cell proliferative disorder.
ECSP066559A (en)
PA8675801A1 (en) ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES
CL2008001682A1 (en) Methods for plant improvement through the use of direct nucleic acid sequence information.
AR057239A1 (en) IMMUNOGLOBULINS
DK1641828T3 (en) Anti-HGF-R antibodies and their use
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
ECSP11011472A (en) ANTAGONISTAS CCR3 ARILSULFONAMIDE 2, 5- DISUSTITUDED
PA8806501A1 (en) TRIAZOLOTRIAZINAS AND TRIAZOLOPIRAZINAS AND ITS USE
CO6470793A2 (en) CCR3 ARILSULFONAMIDE ANTAGONISTS

Legal Events

Date Code Title Description
FG Grant; registration